These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 8637335)

  • 1. Are we ready for factor V Leiden screening?
    Dahlbäck B
    Lancet; 1996 May; 347(9012):1346-7. PubMed ID: 8637335
    [No Abstract]   [Full Text] [Related]  

  • 2. Factor V Leiden--an unselfish gene?
    Hajjar KA
    N Engl J Med; 1994 Dec; 331(23):1585-7. PubMed ID: 7969330
    [No Abstract]   [Full Text] [Related]  

  • 3. Diagnosis of activated protein C resistance (factor V Leiden).
    Baker R; Thom J; van Bockxmeer F
    Lancet; 1994 Oct; 344(8930):1162. PubMed ID: 7934522
    [No Abstract]   [Full Text] [Related]  

  • 4. [Breakthrough in thrombosis research--can the use of contraceptive pills be safer than it used to be?].
    Lähteenmäki P
    Duodecim; 1995; 111(22):2097-8. PubMed ID: 9841168
    [No Abstract]   [Full Text] [Related]  

  • 5. Human genetics. Bad blood by mutation.
    Majerus PW
    Nature; 1994 May; 369(6475):14-5. PubMed ID: 8164730
    [No Abstract]   [Full Text] [Related]  

  • 6. Alternative PCR method for diagnosis of mutation causing activated protein C resistant Gln506-factor V.
    Greengard JS; Xu X; Gandrille S; Griffin JH
    Thromb Res; 1995 Dec; 80(5):441-3. PubMed ID: 8588206
    [No Abstract]   [Full Text] [Related]  

  • 7. The risk of recurrent venous thromboembolism in patients with an Arg506-->Gln mutation in the gene for factor V (factor V Leiden).
    Simioni P; Prandoni P; Lensing AW; Scudeller A; Sardella C; Prins MH; Villalta S; Dazzi F; Girolami A
    N Engl J Med; 1997 Feb; 336(6):399-403. PubMed ID: 9010145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance to activated protein C caused by the factor VR506Q mutation is a common risk factor for venous thrombosis.
    Dahlbäck B
    Thromb Haemost; 1997 Jul; 78(1):483-8. PubMed ID: 9198201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequency of factor V Leiden in Turkey.
    Ozbek U; Tangün Y
    Int J Hematol; 1996 Oct; 64(3-4):291-2. PubMed ID: 8923795
    [No Abstract]   [Full Text] [Related]  

  • 10. Resistance to activated protein C and factor V Leiden as risk factors for venous thrombosis.
    Bertina RM; Reitsma PH; Rosendaal FR; Vandenbroucke JP
    Thromb Haemost; 1995 Jul; 74(1):449-53. PubMed ID: 8578504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance to activated protein C and factor V Leiden.
    Perry DJ; Pasi KJ
    QJM; 1997 Jun; 90(6):379-85. PubMed ID: 9205675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening with the activated protein C resistance assay yields significant savings in a patient population with low prevalence of factor V leiden.
    Taylor LJ; Oster RA; Fritsma GA; Tichenor PH; Reed CE; Eiland BM; Hudson CL; Marques MB
    Am J Clin Pathol; 2008 Mar; 129(3):494-9. PubMed ID: 18285275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance to activated protein C: a major cause of inherited thrombophilia.
    Jensen R; Ens GE
    Clin Lab Sci; 1997; 10(4):219-22. PubMed ID: 10169621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factor profiles in patients with different clinical manifestations of venous thromboembolism: a focus on the factor V Leiden mutation.
    Manten B; Westendorp RG; Koster T; Reitsma PH; Rosendaal FR
    Thromb Haemost; 1996 Oct; 76(4):510-3. PubMed ID: 8902987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of the FVQ506 (factor V Leiden) mutation in the normal and thrombophilic Algerian population.
    Chafa O; Reghis A; Aubert A; Fischer AM
    Br J Haematol; 1997 Jun; 97(3):688-9. PubMed ID: 9207426
    [No Abstract]   [Full Text] [Related]  

  • 16. Factor V Leiden mutation and venous thrombosis.
    Hatake K; Miura Y
    Lancet; 1995 Jan; 345(8942):133. PubMed ID: 7815876
    [No Abstract]   [Full Text] [Related]  

  • 17. [Factor V Leiden and activated protein C resistance].
    Cauchie P; Hilbert P
    Rev Med Brux; 1997 Jun; 18(3):97-102. PubMed ID: 9273603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. World distribution of factor V Leiden.
    Rees DC; Cox M; Clegg JB
    Lancet; 1995 Oct; 346(8983):1133-4. PubMed ID: 7475606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is the prevalence of the factor V Leiden mutation in patients with pulmonary embolism and deep vein thrombosis really different?
    Turkstra F; Karemaker R; Kuijer PM; Prins MH; Büller HR
    Thromb Haemost; 1999 Mar; 81(3):345-8. PubMed ID: 10102457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factor V Leiden: should we screen oral contraceptive users and pregnant women?
    Vandenbroucke JP; van der Meer FJ; Helmerhorst FM; Rosendaal FR
    BMJ; 1996 Nov; 313(7065):1127-30. PubMed ID: 8916702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.